Exscientia plc

NasdaqGM:EXAI Rapport sur les actions

Capitalisation boursière : US$633.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Exscientia Gestion

Gestion contrôle des critères 1/4

Le PDG Exscientia est Dave Hallett, nommé en Feb2023, a un mandat de 1.75 ans. détient directement 0.001% des actions de la société, d'une valeur de $ 7.29K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.8 ans et 3.8 ans.

Informations clés

Dave Hallett

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDGn/a
Durée du mandat du directeur général1.8yrs
Propriété du PDG0.001%
Durée moyenne d'occupation des postes de direction1.8yrs
Durée moyenne du mandat des membres du conseil d'administration3.8yrs

Mises à jour récentes de la gestion

Recent updates

Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others

Aug 08

Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

Jul 17
Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation

Exscientia: Too Much Pessimism

Jun 10

Exscientia: Drug Discovery Platform Attracting Partners And Cash

May 22

Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)

Feb 26

Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Jan 11
Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?

Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 12
Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

Aug 31
New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)

We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Aug 25
We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Jul 21
Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher

Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

Apr 22
Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

Dec 30
We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate

The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Aug 31
The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts

Exscientia: Using AI To Power Drug Development

Aug 15

Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

May 29
Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth

PDG

Dave Hallett (55 yo)

1.8yrs

Titularisation

Dr. David Hallett, also known as Dave, Ph.D. is the Chief Operations Officer of Exscientia Limited since January 2020. He served as Chief Operating Officer at Exscientia plc since June 2022 until 2022 and...


Équipe de direction

NomPositionTitularisationCompensationPropriété
David Hallett
Chief Scientific Officer1.8yrspas de données0.0011%
$ 7.3k
John Overington
Chief Technology Officerless than a yearpas de données0.015%
$ 94.8k
Sara Sherman
Vice President of Investor Relationsno datapas de donnéespas de données
Dan Ireland
Executive VP of Legal & Company Secretary1.8yrspas de donnéespas de données
Parker Moss
Executive Vice President of Corporate Developmentless than a yearpas de donnéespas de données
Caroline Rowland
Chief People Officer2.2yrspas de donnéespas de données
Richard Law
Chief Business Officerno datapas de donnéespas de données
Nikolaus Krall
Executive Vice President of Precision Medicine1.8yrspas de donnéespas de données
Marie-Louise Fjallskog
Interim Chief Medical Officer & Clinical Development Leadless than a yearpas de donnéespas de données

1.8yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de EXAI n'est pas considérée comme expérimentée (ancienneté moyenne 1.8 ans), ce qui suggère une nouvelle équipe.


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
David Hallett
Chief Scientific Officerless than a yearpas de données0.0011%
$ 7.3k
Elizabeth Crain
Independent Non-Executive Chairman3.8yrsUK£282.03k0.088%
$ 557.4k
Mario Polywka
Independent Non-Executive Director7.2yrsUK£201.69k0.052%
$ 330.3k
Robert Ghenchev
Independent Non-Executive Director4.5yrspas de donnéespas de données
Franziska Michor
Independent Director1.5yrsUK£178.86k0.028%
$ 175.7k

3.8yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de EXAI sont considérés comme expérimentés (ancienneté moyenne 3.8 ans).